Acute myeloid leukemia (AML) remains a challenge for both patients and clinicians. Despite improvements in our understanding of the disease and its underlying genetic factors, treatment outcomes still remain poor for many patients.
The development of targeted therapies has shown promise in improving overall survival and patients' quality of life.
As these novel therapies continue to change treatment paradigms at a rapid pace, it is essential that oncologists and other clinicians are able to effectively incorporate these agents into practice to maximize patient outcomes.
